BSX: Other company developments

Item 8.01 Other Events. Investment Agreement with MiRus LLC On May 18, 2026, Boston Scientific Corporation (the “ Company ”) issued a press release announcing that the Company has entered into an investment agreement (the “ Investment Agreement ”) with MiRus LLC (“ MiRus ”), a privately held company developing and commercializing proprietary novel biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the Siegel transcatheter aortic valve replacement system (the “ TAVR System ”), for which it has received investigation device exemption approval from the U.S. Federal Food and Drug Administration (“ FDA ”) to conduct the STAR (Siegel Transcatheter Aortic Valve Replacement Trial) randomized control clinical trial in the United States designed to achieve a Premarket Approval Application for the TAVR System. Under the terms of the Investment Agreement, on May 15, 2026, the Company acquired, for a cash payment of $1.5 billion (exclusive of a $100 million payment previously made by the Company to MiRus) (a) non-voting common equity interests constituting 33.75% of the fully diluted equity interests of MiRus and (b) an exclusive option (the “ Call Option ”) to acquire, subject to the satisfaction of customary closing conditions, all the equity interests of a wholly owned subsidiary of MiRus (such subsidiary, “ TAVR-Structural Heart NewCo ”), to be formed by MiRus to hold all of MiRus’s tangible and intangible assets primarily relating to the business of owning, designing, developing, manufacturing and commercializing the TAVR System, for additional aggregate cash payments totaling $3.0 billion, at the Company’s option following MiRus’ achievement of certain clinical and regulatory milestones, for 100% ownership of